Why semaglutide works — and whether it will work for you

What semaglutide is actually doing inside your body

Your gut releases GLP-1 (glucagon-like peptide-1) naturally after eating. It tells the brain you've had enough, prompts insulin release, and slows food moving out of the stomach. The effect is brief, the hormone breaks down quickly. Semaglutide is a synthetic version engineered to last far longer in the body, so those signals run continuously rather than peaking and fading with each meal.

The result, for most people, is a meaningful reduction in appetite that isn't really a willpower thing. Many patients describe simply forgetting to eat, or feeling satisfied after much smaller portions than usual. The NHS semaglutide medicines page describes this mechanism clearly and is worth reading alongside any consultation.

There's also evidence that semaglutide acts on reward pathways in the brain, reducing the pull of highly processed or calorie-dense foods. This may partly explain why the effect can feel qualitatively different from dieting alone. If you want to go deeper on the biology, our guide covering how semaglutide works walks through the pharmacology in plain language. Food noise (the persistent background thinking about eating) quietens for a lot of people. Not for everyone, but for many.

Why the response varies so much between individuals

This is the part the headline trial numbers can obscure. A 15% average weight loss means some participants lost 5% and others lost 25%. Several factors shape where you land.

Dose matters significantly. The full maintenance dose for Wegovy injection is 2.4mg weekly, reached by titrating up from 0.25mg over several months. People who can't tolerate the higher doses (because of persistent nausea or other GI symptoms) often see a more modest response. That's not a failure of the medicine; it's the biology of tolerability.

Starting weight, metabolic history, and how consistently you maintain the lifestyle changes the treatment is designed to support all shift the outcome. There are specific reasons semaglutide may not produce the expected effect in some people, from absorption issues with the oral tablet to rare cases of biological resistance, a prescriber can help work through these.

One practical check you can do in under a minute: look at which dose you're currently on relative to the licensed schedule, and whether you've been on each step long enough. Many people who feel semaglutide has stopped working are still mid-titration, not yet at the dose where the full effect is usually seen.

How the licensed options differ, and why that affects results

Two semaglutide formulations are licensed for weight loss in the UK. Wegovy as a weekly injection has the longer evidence base, with the full clinical profile covered on our Wegovy page. The Wegovy tablet, approved by the MHRA on 11 June 2026, reaches a 25mg daily maintenance dose via a different titration schedule: 1.5mg, then 4mg, then 9mg, then 25mg. In the OASIS 4 trial, participants who stayed fully adherent to the tablet lost around 17% of body weight over 64 weeks; the average across all participants, regardless of adherence, was around 13.6%.

That adherence gap is worth sitting with. The oral tablet requires a specific routine, first thing in the morning, empty stomach, a small amount of plain water, then nothing to eat, drink, or take for at least 30 minutes. Miss that window and absorption falls sharply. The injection sidesteps this entirely, which is why some patients find it more consistent in practice. Neither is universally better; it depends on your daily life and what you'll actually stick to.

If you're weighing up the costs alongside effectiveness, our Wegovy pricing page sets out what private treatment includes. Understanding what's covered (consultation, clinical review, delivery) matters as much as the headline figure.

What the clinical evidence says about stopping and starting again

The STEP 1 trial and subsequent studies are unambiguous on one point: weight tends to return when semaglutide is stopped, at a rate that reflects how much of the effect was pharmacological rather than behavioural. This isn't unique to semaglutide, it reflects the biology of obesity as a condition rather than a course of treatment. NICE guidance for semaglutide recommends a maximum of two years of use within a specialist service, which is why the question of what comes after treatment matters from the start. Some patients also ask about broader hormonal effects during this period, and whether Wegovy lowers cortisol levels is a question our clinical team has addressed in detail.

If you feel semaglutide has lost its effect partway through treatment, that's a different issue, tolerance and what to do about it is covered separately and is worth reading. But for many people, the question at this stage isn't why it stops, it's whether it will work at all, and whether to try.

That decision is best made with a prescriber who can look at your BMI, any weight-related conditions, your medical history and your expectations as a whole. Semaglutide is a clinically validated tool. It's not effective for everyone in the same way, and a good consultation should say so plainly, not just hand over a pen. If you'd like to speak to our prescribers, your free consultation starts here.